Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Mosquin PL, Rothman KJ. Reanalysis of reported associations of beryllium and lung cancer in a large occupational cohort. J Occup Environ Med. 2017 Mar;59(3):274-81. doi: 10.1097/JOM.0000000000000947
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Schmidt M, Christiansen CF, Mehnert F, Rothman KJ, Sorensen HT. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. Br Med J. 2011 Jul 4;343:d3450. doi: 10.1136/bmj.d3450
Greene BL, Miller JD, Brown TM, Harshman RS, Richerson GT, Doyle JJ. Economic impact of the BP DownShift Program on blood pressure control among commercial driver license employees. J Occup Environ Med. 2009 May 1;51(5):542-53.
Harshman RS, Richerson GT, Hadker N, Greene BL, Brown TM, Foster TS. Impact of a hypertension management/health promotion program on commercial driver's license employees of a self-insured utility company. J Occup Environ Med. 2008 Mar 1;50(3):359-65.
Dreyer NA, Loughlin JE, Lanes SF, Rothman KJ. Mortality among employees of a nuclear power company. J Occup Environ Med. 1988 Jan 1;30(12):988-9.